In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Actavis Laboratories

Division of Teva Pharmaceutical Industries Ltd.

Latest From Actavis Laboratories

Foamix's Minocycline Foam: A Game Changer In Severe Acne?

A topical foam formulation of the antibiotic, minocycline, is expected to be a novel entrant into the US severe acne market. After positive top-line results from a confirmatory Phase III study, Foamix is stepping-up its financing and marketing plans.

Clinical Trials Dermatology

Actavis’ Transformative Dealmaking

A steady stream of M&A and licensing activity, starting with the buyout of Andrx in 2006, spurred Actavis’ a.k.a. Watson’s transformation into a global specialty pharma. This led the way to the 2012 merger with Actavis and now the proposed buyout of Forest, creating a new, global specialty and generics player.

BioPharmaceutical Strategy

Generic OxyContin Criteria Being Developed By FDA Working Group

Having decided that generics must reference reformulated OxyContin, the agency must determine the evidence needed for generics to show they provide equivalent abuse-deterrence.

BioPharmaceutical North America

Patent Expiration May Not Help OxyContin Generics

OxyContin’s method of treatment patent expires April 16, but several patents remain tied up in litigation over APIs as Purdue and generic companies await FDA decision on whether the original formulation can be a reference product.

BioPharmaceutical North America
See All

Company Information